News

BriaCell Presents Positive Data Demonstrating Survival and Clinical Benefits in Advanced Metastatic Breast Cancer at the 2023 AACR

15 of 18 patients remain alive of those recruited since the study reopened in 2021.Longer than expected patient survival data…

2 years ago

Regeneron Announces Retirement of Board Chair, Dr. P. Roy Vagelos, Accomplished Physician-Businessman and Industry Luminary

Dr. Leonard S. Schleifer and Dr. George D. Yancopoulos to become Co-Chairs of the Board and Christine A. Poon to…

2 years ago

Kura Oncology Reports Preclinical Data Highlighting Synergistic Activity of Farnesyl Transferase Inhibitor in Combination with Targeted Therapies

– Preclinical data support the potential for FTIs in combination with KRASG12C inhibitors and TKIs to prevent or delay emergence…

2 years ago

Radiopharm Theranostics Enters Into Supply Agreement with TerThera for Terbium-161 Isotope

Agreement will supply Tb-161 for RAD 602, a potential first in class radiopharmaceutical for treatment of brain cancersSYDNEY, Australia, April…

2 years ago

Aurora Spine Announces Initial Surgeries Conducted Using its SiLO TFX™ MIS Sacroiliac Joint Fixation System

Carlsbad, Calif., April 17, 2023 (GLOBE NEWSWIRE) -- Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV:ASG) (OTCQB: ASAPF), a…

2 years ago

Helius Medical Technologies to Spotlight Expanded Authorizations for its PoNS Device at 2023 American Academy of Neurology Annual Meeting, Booth 1685

MS, Stroke and mmTBI Cover Broader Set of Indications Across North American MarketsNEWTOWN, Pa., April 17, 2023 (GLOBE NEWSWIRE) --…

2 years ago

Gritstone bio Presents 6-month Neutralizing Antibody (nAb) Data at ECCMID 2023 from Two Phase 1 Studies Evaluating Self-amplifying mRNA (samRNA) Against SARS-CoV-2 (CORAL)

-- CORAL-CEPI: Primary series samRNA vaccination elicits strong neutralizing antibody (nAb) responses that persist for at least 6 months, including…

2 years ago

Merck Strengthens Immunology Pipeline with Acquisition of Prometheus Biosciences, Inc.

PRA023 is a novel, late-stage candidate for ulcerative colitis and Crohn’s disease and other autoimmune conditions Prometheus Biosciences’ comprehensive data…

2 years ago

NKGen Biotech, Inc. to Become Publicly Traded Company via Business Combination with Graf Acquisition Corp. IV

NKGen Biotech, Inc. (“NKGen”), a clinical stage Natural Killer (NK) cell therapy company, has entered into a merger agreement with…

2 years ago

Scilex Holding Company Announces Final Postponement of Annual Meeting of Stockholders

PALO ALTO, Calif., April 14, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex”), a subsidiary of Sorrento Therapeutics, Inc.…

2 years ago